Visual Impairment News and Research

Latest Visual Impairment News and Research

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries.

22 Jul 2014

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted.

22 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

LA BioMed researchers launch new project to improve diabetes management

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don't have easy access to the care they need to manage their diabetes.

10 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD).

9 Jul 2014

Study links nearsightedness to higher education and years spent in school

German researchers have found strong evidence that attaining a higher level of education and spending more years in school are two factors associated with a greater prevalence and severity of nearsightedness, or myopia.

28 Jun 2014

New approaches needed to improve visual accessibility for people with low vision-challenges

New approaches and tools are needed to improve visual accessibility for people with low vision in the "real world," according to a special article in the July issue of , official journal of the the American Academy of Optometry.

25 Jun 2014

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

23 Jun 2014

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox S.A., the international ophthalmic company, and Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.).

19 Jun 2014

Simulator for evaluating effects of visual impairment on person's driving performance

The University of California, San Diego School of Medicine is the first ophthalmology department in the nation to feature a fully dedicated high-fidelity, highly realistic driving simulator for evaluating the effects of visual impairment on a person's driving performance.

16 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

Researchers working in Palestine and Jordan to help better provision of eye care

An Aston University academic is working in Palestine and Jordan to help better the provision of eye care in the two countries as part of a €565,000 worldwide two-year project.

29 May 2014

People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression as the general population. And many psychiatric medications can cause vision problems over time.

6 May 2014

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial.

1 May 2014

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye.

30 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Ethics experts issue decision-making guidelines to aid NASA for higher risk human spaceflights

Nearly two years after the conclusion of its space shuttle program left Americans wondering what would become of the spacefaring dreams of decades past, NASA has sought the advice of health and ethics experts for protecting astronauts on its "next generation" of long duration and exploration-class human spaceflights.

3 Apr 2014

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.

3 Apr 2014

Visual Impairment News and Research

Latest Visual Impairment News and Research

Early stage AMD can occur much earlier than previously thought

Study shows correlation between education and nearsightedness

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

LA BioMed researchers launch new project to improve diabetes management

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Integrated therapies can reduce depression by half among people with low vision due to AMD

Study links nearsightedness to higher education and years spent in school

New approaches needed to improve visual accessibility for people with low vision-challenges

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Simulator for evaluating effects of visual impairment on person's driving performance

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Researchers working in Palestine and Jordan to help better provision of eye care

People suffering from vision loss are twice as likely to suffer from depression

Ranibizumab trial gets promising results for CNV

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Ethics experts issue decision-making guidelines to aid NASA for higher risk human spaceflights

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Visual Impairment News and Research

Latest Visual Impairment News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in